Business Context and Reporting Period
This Form 8-K is a current report filed by Silexion Therapeutics Corp on July 21, 2025, regarding events occurring on July 18, 2025. The company is an emerging growth company incorporated in the Cayman Islands with principal executive offices in Ramat-Gan, Israel. Its ordinary shares (SLXN) and warrants (SLXNW) are listed on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only financial threshold referenced is the Nasdaq listing requirement for a minimum of $2.5 million in shareholders' equity, which the company aims to achieve by September 19, 2025.
Material Changes and Listing Status
- Bid Price Deficiency: On July 18, 2025, Nasdaq notified the company that its closing bid price was below the required $1.00 per share for 30 consecutive business days.
- Reverse Share Split: To remedy the deficiency, the company's board approved a 1-for-15 reverse share split, which was ratified by shareholders on July 14, 2025.
- Implementation Timeline: The reverse split is effective after market close on July 28, 2025, with trading on a split-adjusted basis commencing on July 29, 2025.
- Compliance Plan: The company expects to regain compliance with the bid price requirement after 10 consecutive trading days post-split, provided the price remains above $1.00.
Outlook, Risks, and Contingencies
Management has outlined a compliance plan with a hard deadline of September 19, 2025, set by the Nasdaq hearings panel. The company must meet the Equity Standard of $2.5 million in shareholders' equity by this date to maintain its listing.
Key Risks and Uncertainties:
- There is no assurance the company will successfully raise the required shareholders' equity by the September 19, 2025 deadline.
- There is no assurance the reverse share split will result in a sustained bid price above $1.00.
- Failure to meet these standards could result in delisting from the Nasdaq Capital Market.
Investor Verification Checklist
- Verify the effective date and trading symbol adjustments for the 1-for-15 reverse share split on July 29, 2025.
- Monitor the company's progress in raising shareholders' equity to the $2.5 million threshold required by September 19, 2025.
- Review the "Risk Factors" section of the company's Form 10-K for the year ended December 31, 2024, for additional details on listing risks.
- Confirm whether the company has filed any subsequent updates regarding its ability to meet the Nasdaq Equity Standard.